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Ever since Alfred G. Knudson Jr. published his seminal statistical analysis of retinoblastoma, 
scientists have embraced the two-hit hypothesis, which suggested that both copies of tumor 
suppressor genes have to be mutated in order to drive cancer initiation. However, in some cases, 
tumor suppressors do not follow the two-hit rule. A recent Fred Hutch review article, co-authored by 
graduate student Ryan Davis, Staff scientist Dr. Markus Welcker and Principal Investigator Dr. Bruce 
Clurman (Human Biology Division), uses the ubiquitin ligase component and tumor suppressor Fbw7 
as a model to illustrate this point. This review concisely presents the most current research on Fbw7 
and entices us with potential therapeutic opportunities provided by cancers in which Fbw7 is 
mutated. 
Ubiquitin-mediated proteolysis has been implicated in a wide array of biological processes and 
components of the ubiquitin-proteasome system are mutated in many cancers. Large-scale 
sequencing of cancer genomes and mouse modeling experiments have shown that the F-box 
protein Fbw7 is a potent tumor suppressor. "The Fbw7 tumor suppressor is part of a ubiquitin ligase 
that degrades key oncoproteins, including c-Myc, c-Jun, Notch, and cyclin E. Fbw7 binds to 
substrates after they become phosphorylated, which results in their ubiquitylation and subsequent 
destruction by the proteasome", explained Dr. Clurman. Fbw7 is a part of the SCF
Fbw7
 ubiquitin 
ligase (see figure). Within SCF
Fbw7
, Fbw7 functions as an adaptor, providing substrate specificity to 
the SCF
Fbw7
 complex. Substrates that are phosphorylated on a motif known as the Cdc4 
phosphodegron (CPD) bind Fbw7, and three key arginine residues (R465, 479 and R505; hereafter 
Fbw7
ARG
) on Fbw7 that bind CPD are mutational hotspots in cancer. "The inactivating Fbw7 
mutations commonly found in cancers allow oncogenic substrates to accumulate and drives 
carcinogenesis," added Dr. Clurman. 
Many of the well-characterized Fbw7 oncoprotein substrates are transcription factors with 
established or emerging roles in development and tumorigenesis, which highlights Fbw7’s broad 
reach. For instance, c-Myc proteins are known to have profound effects on cancer at least in part 
through its transcriptional control of proliferation, cell growth, metabolism and protein synthesis. 
Importantly, the CPD on c-Myc is mutated in some human Burkitt’s lymphomas, highlighting a 
potential pathological consequence of impaired c-Myc degradation. The authors also point out that  
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mutations in the Notch CPD are mutually exclusive with Fbw7 mutations that occur in T-cell acute 
lymphoblastic leukemia (T-ALL), which emphasizes the impact of Fbw7-dependent Notch 
degradation in T-ALL pathogenesis. 
Because the prognostic value of Fbw7 mutations had remained unclear despite extensive studies, 
the authors performed a meta-analysis (a computational study of previous research) of The Cancer 
Genome Atlas (TCGA), a widely used public database of cancer biology. This analysis confirmed a 
high prevalence of Fbw7
ARG
 mutations, particularly in cancer types where Fbw7 mutations are found 
in more than 10% of cases, such as T-ALL. Notably, the second Fbw7 allele often remained intact, 
contrasting with the classical two-hit scenario. The phenotypes of Fbw7
ARG
 mice are consistent with 
Fbw7
ARG
 acting in a dominant-negative fashion, but why there has been a strong biological selection 
for Fbw7
ARG
mutations, compared to nonsense or null mutations, is still unclear. Because Fbw7 
functions as a dimer in vivo, the authors propose that Fbw7
ARG
 dominantly inhibits the protein 
encoded by the wilde-type allele (Fbw7
WT




 dimers may have substrate-
specific effects. 
The investigators conclude the review by proposing therapeutic strategies to target the Fbw7 
pathway in cancer. The first approach would be to develop small molecule agonists to increase 
substrate affinity towards Fbw7
ARG
. Second, the oncoprotein substrates themselves could be 
targeted, and a previous study showed that pharmacologic inhibition of c-Myc in T-ALL to be a 
potentially viable strategy. Third, a synthetic lethal approach could be employed to identify pathways 
that are essential for the survival of Fbw7-defective, but not normal cells. Finally, a more general 
strategy would be to reduce, but not eliminate Fbw7 function, in such a way to eradicate cancer-
initiating cells of the hematopoietic system, while preserving Fbw7’s tumor-suppressive function in 
solid tissues. Overall, this review showed that our understanding of Fbw7’s tumor suppressive 
function has progressed tremendously over the past 5 years, through identification of substrates, 
mouse modeling, and studying the unique biological and oncogenic properties of 
Fbw7
ARG
 mutations. The network of oncogenic pathways regulated by Fbw7 offers a glimpse into 
how to target this pathway in the clinic. 
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Image provided by Mr. Ryan Davis. 
The Fbw7 protein binds both to the remainder of the SCF complex 
(Skp-1, Cullin-1, Rbx1 and an E2 enzyme) and its oncogenic 
substrates (purple ovals). This binding leads to substrate 
ubiquitylation (light blue hexagons) and degradation by the 
proteasome (purple hexagons). This degradation is impaired in many 
Fbw7-mutated cancers. 
 
